Yes, Azithromycin Frequently Fails to Cover Strep Due to Macrolide Resistance
Azithromycin should only be used for strep pharyngitis in patients with significant penicillin allergy, and even then, susceptibility testing must be performed because macrolide resistance rates are clinically significant and geographically variable. 1, 2
The Resistance Problem
Macrolide resistance in Group A Streptococcus (GAS/Streptococcus pyogenes) is well-documented and varies substantially by region:
- United States: Resistance rates of 5-8% in recent years, though some studies show rates as high as 15% 3, 4
- Geographic variation is extreme: Rates range from 3.7% (Sweden) to 31% (Italy) 5
- Wisconsin study (2011-2015): 15% of GAS isolates were nonsusceptible to both erythromycin and azithromycin 4
The FDA label explicitly warns: "Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin" 2. This is not optional guidance—it's a clear directive that resistance is common enough to warrant routine testing.
Clinical Consequences of Treatment Failure
The stakes are high. Macrolide treatment failure has resulted in:
- Acute rheumatic fever in documented cases where macrolide-resistant strep was treated with azithromycin 6
- Rheumatic heart disease, the leading cause of acquired heart disease in children worldwide 6
- Emergence of resistance during treatment: Studies show GAS can acquire resistance genes (mef(A) or erm(B)) or develop ribosomal mutations during azithromycin therapy 7
Guideline Recommendations
Both major U.S. guidelines are unequivocal:
IDSA 2012: Lists azithromycin as an alternative only for penicillin-allergic patients, with "strong, moderate" evidence quality. The guideline explicitly notes: "Resistance of GAS to these agents is well-known and varies geographically and temporally" 1
AHA 2009: States macrolide resistance rates in the U.S. are approximately 5-8%, and emphasizes that "strains of GAS resistant to these agents have been highly prevalent in some areas of the world, which has resulted in treatment failures" 3
When to Use (and Not Use) Azithromycin
DO NOT USE azithromycin as first-line therapy
- Penicillin or amoxicillin remain the drugs of choice 1, 3
- Benzathine penicillin G is preferred for compliance concerns 1
ONLY USE azithromycin when:
- Significant penicillin allergy exists (not minor rash—true hypersensitivity) 1, 2
- AND susceptibility testing is performed 2, 4
- Consider first-generation cephalosporins (cephalexin, cefadroxil) or clindamycin as superior alternatives for penicillin allergy, as they have lower resistance rates 1, 3
Critical Pitfall to Avoid
The most dangerous error is assuming azithromycin "covers strep" without testing. Approximately 1% of initially azithromycin-susceptible strains became resistant following therapy in clinical trials 2. In real-world practice with baseline resistance of 5-15%, you're gambling with a 1-in-7 to 1-in-20 chance of treatment failure—unacceptable odds when penicillin has zero resistance and prevents rheumatic fever.
The evidence is clear: azithromycin is a second-line agent at best, requires susceptibility testing, and should be reserved only for patients who cannot receive penicillin or cephalosporins 1, 3, 2, 6.